---
title: "Danaher sees earnings lift from Masimo deal and bioprocessing rebound"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292939444.md"
description: "Danaher anticipates earnings growth driven by the recovery in bioprocessing demand and contributions from its $9.9 billion Masimo acquisition. The deal is expected to add 15-20 cents to adjusted EPS in its first full year, with $125 million in cost savings targeted. Danaher plans to improve Masimo's margins while its core life sciences business emerges from destocking, supported by rising equipment orders and high single-digit bioprocessing growth guidance."
datetime: "2026-07-16T18:11:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292939444.md)
  - [en](https://longbridge.com/en/news/292939444.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292939444.md)
---

# Danaher sees earnings lift from Masimo deal and bioprocessing rebound

According to CNBC, Danaher is expected to accelerate earnings as bioprocessing demand recovers and its recently closed $9.9 billion acquisition of Masimo begins to contribute. New CFO Matthew Gugino said on the first-quarter earnings call in April that the deal is expected to add roughly 15 to 20 cents to adjusted earnings per share in the first full year after closing, and Danaher is targeting $125 million in cost savings. The article also said Danaher expects to improve Masimo's margins through procurement, manufacturing and sales execution, while its core life sciences business is emerging from a two-year post-pandemic destocking period. It added that equipment orders have risen sequentially for three straight quarters, book-to-bill has normalized and management has guided for high single-digit growth in bioprocessing this year.

### Related Stocks

- [DHR.US](https://longbridge.com/en/quote/DHR.US.md)
- [MASI.US](https://longbridge.com/en/quote/MASI.US.md)

## Related News & Research

- [Key facts: Danaher strong cash; trims 2026 outlook; bio orders, $100M deferred](https://longbridge.com/en/news/293434927.md)
- [Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook](https://longbridge.com/en/news/293324241.md)
- [BUZZ-Street View: Bioprocess woes weigh on Danaher, but bulls stay put](https://longbridge.com/en/news/293441431.md)
- [Stock Of The Day: Is The Danaher Selloff Over?](https://longbridge.com/en/news/293517409.md)
- [DHR: Raised 2026 guidance after strong Q2 results, robust orders, and successful Masimo acquisition](https://longbridge.com/en/news/293354828.md)